Orion is known for its commercial presence in the European respiratory business space. Our device technology platform has enabled, for instance, the development of a portfolio of inhaled drug products.
However, achieving this position is attributable not only to our technological expertise but also to the value-adding collaborations with our many business partners. Successful partnership management and collaborations throughout the value chain are priorities for us.
While we maximise the value of our respiratory assets together with our partners, we also look to expand our business through in-licensing and the acquisition of marketed, ready-to-market or late-stage assets that would be synergistic to our European respiratory portfolio.
Our focus indications are asthma and chronic obstructive pulmonary disease (COPD), but we are also interested in other indications such as allergy.
We are eager to get to know new potential licensing partners for in-licensing and out-licensing as well as partners and vendors interested in developing technology, products, and production processes with us.
We are also looking for partners who would be interested in placing their molecules in Orion's Dry Powder Inhaler platform.
Our work is always global. Outside Europe, we mostly work with our partners through Partner Sales.
Do you want Orion to contact you? Please fill out the details of your enquiry below.